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The killing effect of various antimicrobial agents used in the therapy of Salmonella
typhi infection was tested against Salm. typhi strain Ty2 after phagocytosis by
human monocyte-derived macrophages. The macrophages, cultured in 96-well
microtitre plates, were infected for 1 h at 37°C by opsonized Salm. typhi Ty2 at a
bacteria-cell ratio of 9:1. When added to the infected macrophage monolayers, at
one and ten times the MIC, ampicillin, ceftriaxone and pefloxacin appeared to be
highly bactericidal ( < 0-25 logl0 cfu/well after 20 h, against 4 log10 cfu/well in
antibiotic-free controls). Trimethoprim-sulphamethoxazole was bactericidal at ten
times the MIC, but not at the MIC. Chloramphenicol was mostly bacteriostatic at
the concentrations tested. As a control, gentamicin (10mg/l) did not exhibit any
significant antibacterial effect, indicating that most or all the bacteria recovered from
lysed cells were intracellular. Other controls for phagocytosis were also performed
with heat-killed Candida albicans. Our results seem to correlate with the known
clinical effect of some antimicrobials in human Salm. typhi infection. The in-vitro
assay described here may be useful for assessing the activity of antimicrobial agents
against Salm. typhi infection.
Introduction
Typhoid fever is still a major public health problem associated with significant
morbidity and mortality in many countries (Edelman & Levine, 1986). Since Salmonella
typhi is a pathogen confined to humans, no suitable animal model is available for
testing the therapeutic efficacy of potential treatments for this disease. Salmonella sp.
are capable of entering cells and lie within the phagolysosomes of the host cells in an
acidic environment (Carrol el al., 1979), conditions which may protect them from the
effects of antimicrobials unable to enter cells or inactivated by low pH. Thus, it is not
surprising that for treating typhoid fever and chronic carriers of Salm. typhi certain
antibiotics are ineffective despite good in-vitro activity (Hornick el al., 1970).
Therefore, alternative methods for testing the susceptibility of Salm. typhi to antimicro-
bial agents are needed. Recently, we have shown that Salm. typhi is able to survive
within human monocyte-derived macrophages (Vladoianu, Chang & Pechere, 1990).
Here we report on the in-vitro effects of ampicillin, ceftriaxone, chloramphenicol,
pefloxacin and trimethoprim-sulphamethoxazole against Salm. typhi Ty2 when phago-
cytosed by human monocyte-derived macrophages.
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Materials and methods
Bacteria
The virulent, smooth Ty2 strain of Salm. typhi Vi +, used by us in previous studies
(Vladoianu et al., 1965, 1990), was cultured on Tryptone Soya agar (Oxoid Ltd.,
Basingstoke, UK) for 18 h at 37°C. After opsonization with human normal serum
(30 min, 37°C) a suspension of the bacteria was made in medium 199 (Ml99; Seromed,
Munich, FRG) supplemented with 10% heat-inactivated (60 min, 56°C) normal serum,
corresponding to a turbidity of 10 international opacity units/ml (WHO, 1954). From
this suspension, a series of ten-fold dilutions was prepared in the same medium. One of
these dilutions served as inoculum while others were used to count the viable bacterial
cells as colony forming units (cfu) by a pour-plate technique.
Antimicrobial agents and MIC determinations
The antimicrobial agents used in this study were: ampicillin (Beecham Laboratories,
Brentford, England), ceftriaxone (Hoffman La Roche and Co. Ltd, Basel, Switzerland),
chloramphenicol (Calbiochem-Behring Corp.), trimethoprim-sulphamethoxazole
(Lagap Pharma AG, Zug/Vezia, Switzerland), pefloxacin mesylate (Roger Bellon,
Paris, France), and gentamicin (Seromed, Munich, FRG). All compounds were diluted
in culture medium after being dissolved according to manufacturer's instructions.
The minimal inhibitory concentrations (MIC) of antimicrobials for Salm. typhi Ty2
were determined as previously described (Michea-Hamzehpour et al., 1987).
Preparation of human monocyte-derived macrophages
Human monocyte-derived macrophages were obtained as previously described
(Vladoianu et al., 1990). Human mononuclear cells were obtained from the blood of
human volunteers serologically negative for hepatitis B, syphilis and HIV, and without
a history of typhoid fever or vaccination against typhoid. Heparinized blood was
overlaid on Ficoll-Paque (Pharmacia, Uppsala, Sweden) and centrifuged at 450 # for
30 min. The purified mononuclear cells were dispensed into the wells of 96-well
microtitre plates (Costar, Cambridge, MA, USA. After overnight incubation at 37°C
the non-adherent cells were discarded by washing with prewarmed Ml99 and fresh
Ml99 with 10% serum was added. The medium was replaced every three days and the
monolayers were used after 12-14 days of incubation when the macrophages showed
complete differentiation. The number of macrophages per well was approximately 103
cells, as assessed by microscopy and by measuring the protein content of the wells
against a previously constructed standard curve. Cell viability was always > 95% as
tested by the trypan blue exclusion test (Boyse, Old & Chouroulinkov, 1964). The
phagocytic ability of macrophages was tested by their phagocytosis of heat-killed
Candida albicans (30 min, 100°Q (Smith & Rommel, 1977).
Jn-vitro assay of bacterial survival within macrophages
This assay was performed as previously described (Vladoianu et al., 1990). After
discarding the Ml99-10% serum from the wells, adherent macrophage monolayers
were infected with Salm. typhi Ty2 by adding 100 /tl of a suspension (in M199-10%
serum) containing approximately 9xl06cfu/ml Salm. typhi Ty2. The bacterial-cell
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ratio was 9:1. The cell monolayers were incubated for 1 h at 37CC, the wells were then
washed twice and some monolayers were lysed with 0 1 % Triton X-100 at 4°C. Test
wells received the antibiotics in Ml99-10% serum at concentrations of one and ten
times their previously determined extracellular MIC, and were incubated for 19 h.
Control wells included antibiotic-free wells and wells containing gentamicin, which is
only active against extracellular Salm. typhi, at a concentration of 10 mg/1; (the MIC of
gentamicin for extracellular Salm. typhi Ty2 was 0-30 mg/1). At the end of the
incubation period, the wells were washed three times and the remaining cell monolayers
were lysed with 0-1% Triton X-100 at 4°C. The cfu were counted from the lysed
homogenates. The bacteria recovered from the lysed homogenates were tested for their
antibiotic susceptibility in order to confirm that survival within monolayers was not the
result of the development of antibiotic resistance.
Toxicity controls and statistical tests
Controls for the toxicity of the antimicrobials on human-monocyte derived macro-
phages were performed by using the trypan blue dye exclusion test (Boyse et al., 1964).
Data are reported as the mean ±SEM. Significance was assessed by using Student's
r-test; a P value < 0-05 was considered significant.
Results
MICs of antibiotics for extracellular Salm. typhi Ty2 were: ampicillin, 0-5 mg/1;
ceftriaxone, 0-1 mg/1; chloramphenicol, 2-2 mg/1; pefloxacin, 0-05 mg/1; and trimetho-
prim-sulphamethoxazole, 0-05/0-25 mg/1. The effects of antimicrobials against phagocy-
tosed Salm. typhi Ty2, at one and ten times their respective MIC are shown in Figure 1.
At 20 h after infection, control monolayers had a mean of 104 cfu/well. Control wells
with gentamicin (10 mg/1) yielded high bacterial counts indicating that in our experi-
ments most or all the Salm. typhi recovered were intracellular. Ampicillin, ceftriaxone
and pefloxacin showed good killing ( < 0-25 logl0 cfu/well) at both one and ten times
their MIC (P < 0-001, compared with antibiotic-free controls). Chloramphenicol and
trimethoprim-suphamethoxazole showed limited killing at the MIC ( > 2 log,0 to
< 3 log,0 cfu/well). At ten times the MIC, trimethoprim-sulphamethoxazole showed
good killing whereas chloramphenicol still remained bacteriostatic (1-45 log,0 cfu/well).
None of the antibiotics tested was toxic for the macrophage monolayers at the
concentrations used, as shown by the trypan blue dye exclusion test (data not shown).
The in-vitro susceptibility of extracellular bacteria and bacteria recovered from lysed
macrophages was identical showing that the surviving bacteria had not acquired
resistance after drug exposure.
Discussion
Ampicillin, ceftriaxone and pefloxacin, but not chloramphenicol, were clearly bacteri-
cidal against phagocytosed Salm. typhi Ty2. Trimethoprim-sulphamethoxazole was
found to be bactericidal at ten times the MIC, but not at the MIC. The observation
that gentamicin was ineffective against intracellular Salm. typhi despite a low extra-
cellular MIC is in agreement with previous reports (Lissner, Swanson & O'Brien, 1983;
Vladoianu et al., 1990). The concentrations of antimicrobials used in our in-vitro assays
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Figure 1. Effects of antimicrobial* on the survival of Salm. typhi Ty2 phagocytosed by human monocyte-
derived macrophages as assessed by the number of bacteria recovered from lysed cells (l°gio cfu/well). The
bacteria-cell ratio was 9:1 (9x lO'cfu/lO3 cells). # , Controls; O, ampicillin; V, ceftriaxone; O, chloram-
phenicol; A, pefloxacin; D, trimethoprim-sulphamethoxazole. (a) Antimicrobials added at the MIC. (b)
Antimicrobials added at 10 times the MIC. Results for each point represents the mean ±S.E.M. of four wells.
are within achievable levels in the blood of patients treated with standard dosages of
these compounds (Thomsberry & Sabath, 1985).
Salm. typhi and other Salmonella spp. are susceptible to many antibiotics in vitro, but
the in-vitro response correlates poorly with the in-vivo response (Hook, 1985).
Salmonellae are bacteria capable of penetrating cells and multiplying within phagocytic
cells (Cairol et al., 1979), and the discrepancy between the results of in-vitro tests and
clinical findings may be due to the failure of some antibiotics to penetrate phagocytic
cells adequately. Although the intracellular concentrations of the antimicrobials tested
were not determined in the present study, our results suggest that all these compounds
were able to penetrate macrophages. Chloramphenicol, trimethoprim and quinolones
are known to penetrate phagocytic cells at different rates (Prokesch & Hand, 1982;
Easmon & Crane, 1985; Koga, 1987; Hand & King-Thompson, 1989). Penicillins and
cephalosporins have the reputation of concentrating poorly in polymorphonuclear
leucocytes (Prokesch & Hand, 1982; Koga, 1987), hence possessing limited intracellular
bioactivity (Vosbeck, James & Zimmermann, 1984). However, our results showing the
effects of ampicillin and ceftriaxone on intracellular Salm. typhi suggest that these
compounds were able to enter human monocyte-derived macrophages. There is the
possibility that these compounds entered human monocyte-derived macrophages by
pinocytosis, as has been shown for cephalosporins where they are able to kill phagocy-
tised Staphylococcus aureus when the killing mechanisms of the monocytes have been
blocked (Van den Broek et al., 1986). Moreover, ceftriaxone has been shown to be
concentrated within phagocytes in vivo (Kuhn, Angehrn & Havas, 1986). Further
Antimicrobials and intraphagocytie S. typhi 693
studies using systems such as those described by us may help in the selection of
compounds active against Salm. typhi within phagocytes.
Our results correlate well with the known clinical effect of antimicrobials in human
Salm. typhi infection. Chloramphenicol has been regarded as the drug of choice for the
treatment of typhoid fever (Hook, 1985). However, chloramphenicol therapy has a
high relapse rate and is not effective in treating chronic enteric carriers (Hornick et al.,
1970; Hook, 1985). Chloramphenicol did not exert a bactericidal effect on intraphago-
cytie Salm. typhi and probably therapy in vivo is not always able to eradicate the
bacteria from the phagocytes completely. Trimethoprim-sulphamethoxazole has been
used for the treatment of typhoid fever and for the treatment of chronic enteric carriers
with variable results, ranging from equivalence to chloramphenicol to an unsatisfactory
response (Hook, 1985). Among the factors causing this variability in results, adminis-
tration of insufficient doses of trimethoprim-sulphamethoxazole has been postulated
(Hook, 1985). Our results might support this observation because Salm. typhi was
eradicated from human-monocyte derived macrophages only when they were exposed
to the highest concentration tested. Ampicillin has been used for the treatment of
typhoid fever and has been considered as the treatment of choice for chronic enteric
carriers who have normally functioning gallbladders without evidence of cholelithiasis
(Simon & Miller, 1966; Phillips, 1971). Part of the efficacy of this antibiotic might be
explained by the bactericidal effect of ampidUin on intracellular Salm. typhi. Third
generation cephalosporins and quinolones have recently been used for the treatment of
both typhoid fever and chronic enteric carriers and found to be useful for these
indications (Bryan, Rocha & Scheld, 1986; Soe & Overturf, 1987; Murray, 1989;
Waldvogel, 1989). Again, an important factor in the efficacy of these antibiotics is
probably their good intracellular bioactivity. From an epidemiological viewpoint, since
these antibiotics seem not to yield a temporary Salm. typhi carrier state, as observed
with chloramphenicol, they may be playing a major role in blocking secondary
transmission of Salm. typhi and thereby preventing outbreaks of typhoid fever (Bryan
et al., 1986; Soe & Overturf, 1987; Murray, 1989; Waldvogel, 1989).
In conclusion, the present studies may help to provide a rationale for the selection
and administration of effective antimicrobials in the treatment of typhoid fever and
chronic carriers of Salm. typhi.
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